These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37369494)

  • 21. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
    Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
    Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
    Acharya B; Chaijaroenkul W; Na-Bangchang K
    J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
    Brandi G; Relli V; Deserti M; Palloni A; Indio V; Astolfi A; Serravalle S; Mattiaccio A; Vasuri F; Malvi D; Deiana C; Pantaleo MA; Cescon M; Rizzo A; Katoh M; Tavolari S
    Sci Rep; 2024 Feb; 14(1):3136. PubMed ID: 38326380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
    Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
    Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infigratinib in patients with advanced cholangiocarcinoma with
    Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
    Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Futibatinib for
    Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
    N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
    Spahn S; Kleinhenz F; Shevchenko E; Stahl A; Rasen Y; Geisler C; Ruhm K; Klaumuenzer M; Kronenberger T; Laufer SA; Sundberg-Malek H; Bui KC; Horger M; Biskup S; Schulze-Osthoff K; Templin M; Malek NP; Poso A; Bitzer M
    Nat Commun; 2024 Feb; 15(1):1287. PubMed ID: 38346946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
    Huang C; Wen Q; Chen J; Zhong H; Xiang X; Xiong J; Deng J
    Cancer Treat Res Commun; 2022; 31():100568. PubMed ID: 35477128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways.
    Jaidee R; Kongpetch S; Senggunprai L; Prawan A; Kukongviriyapan U; Kukongviriyapan V
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1681-1690. PubMed ID: 32383028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infigratinib for cholangiocarcinoma.
    Sadeghi S
    Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
    Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.